Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease

Respiratory Investigation

Volumn 51, Issue 2, 2013, Pages 69-75

  Ando, Katsutoshi ^a   Motojima, Shinji ^b   Doi, Tokuhide ^c   Nagaoka, Tetsutaro ^a   Kaneko, Norihiro ^b   Aoshima, Masahiro ^b   Takahashi, Kazuhisa ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KAMEDA MEDICAL CENTER   (Japan)

^c Fukuoka Clinic   (Japan)

Author keywords

Cyclophosphamide; Glucocorticoid monotherapy; Interstitial lung disease; Pulmonary function; Systemic sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; GLUCOCORTICOID; PREDNISOLONE;

ADULT; ARTICLE; COHORT ANALYSIS; COMPRESSION FRACTURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED VITAL CAPACITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERSTITIAL LUNG DISEASE; JAPANESE; LIVER DYSFUNCTION; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATIENT ASSESSMENT; PNEUMOTHORAX; PROGNOSIS; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SURVIVAL TIME; SYSTEMIC SCLEROSIS;

FEMALE; GLUCOCORTICOIDS; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PROGNOSIS; SCLERODERMA, SYSTEMIC; SURVIVAL RATE;

EID: 84879275284     PISSN: 22125345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resinv.2012.12.002     Document Type: Article

References (21)

1. Steen V.D., Conte C., Owens G.R., et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37:1283-1289.
2. Chang B., Wigley F.M., White B., et al. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003, 30:2398-2405.
3. Altman R.D., Medsger T.A., Bloch D.A., et al. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991, 34:403-413.
4. Steen V.D., Medsger T.A. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000, 43:2437-2444.
5. Tashkin D.P., Elashoff R., Clements P.J., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666.
6. Holeys R.K., Ellis R.W., Wellsbury J., et al. A multicenter, prospective, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006, 54:3962-3970.
7. Airo P., Danieli E., Parrinello G., et al. Intravenous cyclophosphamide therapy for systemic sclerosis: a single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 2004, 22:573-578.
8. Steen V.D., Medsger T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998, 41:1613-1619.
9. Dheda K., Lalloo U.G., Cassim B., et al. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004, 23:306-309.
10. Travis W.D., Matsui K., Moss J., et al. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000, 24:19-33.
11. The Japanese Respiratory Society. Nonspecific interstitial pneumonia (NSIP). Idiopathic interstitial pneumonias: diagnosis and treatment. 2nd ed. Nankodo; 2011. p. 74-82.
12. Charlson M.E., Pompei P., Ales K.L., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
13. Sumikawa H., Johkoh T., Colby T.V., et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 2008, 177:433-439.
14. Mukerjee D., George D., Knight C., et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004, 43:461-466.
15. Sharp D.S. Reference values for lung function in the Japanese: recording of normal lung function from 11 institutes in Japan. Jpn J Thoracic Dis 1993, 31:421-427.
16. Tashkin D.P., Elashoff R., Clements P.J., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007, 176:1026-1034.
17. Clements P.J., Roth M.D., Elashoff R., for the Scleroderma Lung Study Group, et al. Scleroderma Lung Study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 2007, 66:1641-1647.
18. Nadashkevich O., Davis P., Fritzler M., et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006, 25:205-212.
19. Nishijima C., Sato S., Hasegawa M., et al. Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatology (Oxford) 2001, 40:406-409.
20. Steen V., Medsger T.A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003, 48:516-522.
21. Trad S., Amoura Z., Beigelman C., et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006, 54:184-191.